Condition: Focal Seizure · Epilepsy · Focal Epilepsy · Sponsor: Rapport Therapeutics Inc.
This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.
This description comes directly from the study's public registry record.
Rapport Medical · 857 323 9048 · RAP-219-FOS@rapportrx.com
Always discuss trial participation with your own doctor first.
| Pillar Clinical Research | Bentonville, Arkansas, United States | Recruiting |
| Colorado Springs Neurological Associates | Colorado Springs, Colorado, United States | Recruiting |
| K2 Medical Research | Maitland, Florida, United States | Recruiting |
| Velocity Clinical Research | Raleigh, North Carolina, United States | Recruiting |
| University of Texas Health Science Center in Houston | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07594119